16:53 EST Acadia Pharmaceuticals (ACAD) sees FY26 revenue $1.22B-$1.28B, consensus $1.2B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals initiated with an Outperform at Wolfe Research
- Acadia Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
- ACAD Upcoming Earnings Report: What to Expect?
- ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch
- Acadia Pharmaceuticals price target raised to $23 from $21 at Oppenheimer